Who are Curevo Vaccine's investors?

Curevo Vaccine's investors include Adjuvant Capital, OrbiMed, RA Capital, Sanofi Ventures, HBM Healthcare Investments, Janus Henderson Investors, Medicxi.

Curevo Vaccine

Founded 2017 · 43 employees on LinkedIn · 9 known investors

Find your way into Curevo Vaccine

Each arrow is one introduction. Sign up to fill in the first one.

389 people can intro you to George

Ask Kabeer Aziz to introduce you to George Simeon

You →Kabeer · together at Curevo Vaccine →George

90 people can intro you to Guy

Ask Jamie Chen to introduce you to Guy De La Rosa

You →Jamie · together at Curevo Vaccine →Guy

Your email: who you already know at Curevo Vaccine, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Curevo Vaccine team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases. It operates in clinical-stage vaccine development.

Biotech Healthtech

Founders & leadership

George Simeon CEOGeorge Simeon held executive roles at Johnson & Johnson, Novartis, and SK Telecom before serving as CEO of Curevo Vaccine, where he led the company through clinical development and its acquisition by Eli Lilly; he brings over 30 years of healthcare industry experience across biotechnology, pharmaceuticals, medical devices, and diagnostics.

Gregory S. CurhanCFO

Guy De La Rosa CMOGuy De La Rosa is Chief Medical Officer at Curevo Vaccine, a clinical-stage biotech company developing non-mRNA vaccines for infectious diseases. He is board-certified in internal medicine and infectious diseases, with experience in clinical research and medical affairs in the pharmaceutical industry.

Investors · 9

Adjuvant Capitallisted by Adjuvant CapitalNew York · $10M – $25M

How we know: Adjuvant Capital's portfolio page · statnews.com · Not right? Tell us

OrbiMedlisted by OrbiMedNew York · $1M – $75M

How we know: OrbiMed's portfolio page · funding news · statnews.com · the VCSheet dataset · Not right? Tell us

RA Capitallisted by RA CapitalBoston

How we know: RA Capital's portfolio page · funding news · statnews.com · Not right? Tell us

Sanofi Ventureslisted by Sanofi VenturesCambridge · $5M

How we know: Sanofi Ventures's portfolio page · funding news · statnews.com · the VCSheet dataset · Not right? Tell us

HBM Healthcare InvestmentsreportedZug

How we know: funding news · Not right? Tell us

Janus Henderson InvestorsreportedLondon

How we know: statnews.com · Not right? Tell us

MedicxireportedLondon

How we know: funding news · statnews.com · Not right? Tell us

Also in the syndicate · 2

GC BiopharmaHBM Healthcare Investors

Funding

SEC filings, press & company announcements

Undisclosed amountSeries BMar 2025
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

$60 Million Funding Supports Shingles Vaccine Candidate - Curevo Vaccinecurevovaccine.com · Feb 2022

Vaccine startup Curevo takes on pharma giant GSK, raises $60M for trial of shingles shot - Curevo Vaccinecurevovaccine.com · Feb 2022

News - Curevo Vaccinecurevovaccine.com · May 2021

Frequently asked questions

What does Curevo Vaccine do?: Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases. It operates in clinical-stage vaccine development.
Who are Curevo Vaccine's investors?: Curevo Vaccine's investors include Adjuvant Capital, OrbiMed, RA Capital, Sanofi Ventures, HBM Healthcare Investments, Janus Henderson Investors, Medicxi.